Mechanism of action of Fuzheng Huayu prescription in treatment of liver cancer based on network pharmacology

Jingshu QI; Dabing PING; Xin SUN; Jingbo XUE; Yanyan TAO; Yuan PENG; Chenghai LIU

doi:10.3969/j.issn.1001-5256.2021.10.016

Volume 37 Issue 10

Oct. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(10): 2338-2342

PDF( 2138 KB)

Mechanism of action of Fuzheng Huayu prescription in treatment of liver cancer based on network pharmacology

DOI: 10.3969/j.issn.1001-5256.2021.10.016

Jingshu QI¹,
Dabing PING¹,
Xin SUN²,
Jingbo XUE¹,
Yanyan TAO¹,
Yuan PENG^{1
,
,},
Chenghai LIU^{1, 2, 3, 4
,
,}

1.
Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2.
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China
3.
Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai 201203, China
4.
Shanghai Innovation Center of TCM Health Service, Shanghai 201203, China

Research funding:

National Natural Science Foundation of China (81730109);

National Natural Science Foundation of China (81874363);

National Science and Technology Major Project during the 13th Five-Year Plan Period (2018ZX10302204);

Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201)

Received Date: 2021-02-09
Accepted Date: 2021-03-17
Published Date: 2021-10-20

Abstract

Abstract

Objective To investigate the mechanism of Fuzheng Huayu(FZHY) decoction in the treatment of liver cancer based on network pharmacology. Methods TCMSP, BATMAN, and Drugbank databases were searched for the main chemical components and corresponding targets of FZHY, and STRING database was used to perform a PPI network analysis. Cytoscape software was used to establish a drug-disease network model and perform a network analysis, and R language was used to perform GO and KEGG enrichment analysis of targets. Results A total of 192 intersection genes between FZHY and liver cancer and 95 potential compounds were screened out, among which quercetin and luteolin were the active components with an important regulatory role. INS, IL-6, and EGFR were the key targets for the potential effect of FZHY. The GO enrichment analysis showed the involvement in various biological processes such as response to drug and response to oxygen level, and the KEGG enrichment analysis showed the involvement in the signaling pathways including apoptosis and tumor necrosis factor signaling pathways. Conclusion Based on the method of network pharmacology, this study reveals the mechanism of action of multiple targets and targets of FZHY in the treatment of liver cancer, which provides a theoretical basis for clinical and basic scientific research.
- Liver Neoplasms,
- Fuzheng Huayu Decoction,
- Network Pharmacology

FullText(HTML)

References(24)

References

[1]	GE JB, XU YJ. Internal medicine[M]. 9th ed. Beijing: People's Medical Publishing House, 2018. 葛均波, 徐永健. 内科学[M]. 第9版. 北京: 人民卫生出版社, 2018.
[2]	FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): e359-e386. DOI: 10.1002/ijc.29210.
[3]	BERTUCCIO P, TURATI F, CARIOLI G, et al. Global trends and predictions in hepatocellular carcinoma mortality[J]. J Hepatol, 2017, 67(2): 302-309. DOI: 10.1016/j.jhep.2017.03.011.
[4]	National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003. 中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
[5]	LIU C, HU Y, XU L, et al. Effect of Fuzheng Huayu formula and its actions against liver fibrosis[J]. Chin Med, 2009, 4: 12. DOI: 10.1186/1749-8546-4-12.
[6]	LIU L, ZHANG HX, CHEN L, et al. Effect of Fuzheng Huayu decoction on the expression of MMP-3 and ESM-1 in patients with hepatocellular carcinoma[J]. China J Chin Med, 2019, 34(5): 1065-1069. DOI: 10.16368/j.issn.1674-8999.2019.05.252. 刘莲, 张红霞, 陈蕾, 等. 扶正化瘀方对肝癌患者MMP-3和ESM-1表达的影响[J]. 中医学报, 2019, 34(5): 1065-1069. DOI: 10.16368/j.issn.1674-8999.2019.05.252.
[7]	JI G, CAO CL, LIU P, et al. Pathology and immunohistochemistry research on effects of Fuzheng-Huayu prescription on hepatocyte proliferation of cirrhosis rats[J]. Chin J Basic Med Tradit Chin Med, 2001, 7(2): 29-32. DOI: 10.3969/j.issn.1006-3250.2001.02.015. 季光, 曹承楼, 刘平, 等. 扶正化瘀方影响肝硬化大鼠肝细胞增殖的病理及免疫组化研究[J]. 中国中医基础医学杂志, 2001, 7(2): 29-32. DOI: 10.3969/j.issn.1006-3250.2001.02.015.
[8]	JI G, CAO CL, LIU P, et al. The study on inhibiting effect of Fuzhenghuayufang on hepatocarcinoma induced by DMN in rat[J]. Chin J Integr Trad West Med Digestion, 2001, 9(1): 20-22. DOI: 10.3969/j.issn.1671-038X.2001.01.007. 季光, 曹承楼, 刘平, 等. 扶正化瘀方预防大鼠肝癌形成机制的研究[J]. 中国中西医结合消化杂志, 2001, 9(1): 20-22. DOI: 10.3969/j.issn.1671-038X.2001.01.007.
[9]	LIU P, LIU C, WANG XS, et al. Fuzheng Hua yu Recipe and Yangyin Rou gan Recipe in preven ting hepatocarcinoma of rats[J]. Chin J Exp Tradit Med Form, 1996, 2(3): 35-40. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX603.010.htm 刘平, 刘成, 王晓素, 等. 扶正化瘀方与养阴柔肝方预防大鼠实验性肝癌的研究[J]. 中国实验方剂学杂志, 1996, 2(3): 35-40. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX603.010.htm
[10]	ZHOU J, SUN HC, WANG Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition)[J]. Liver Cancer, 2018, 7(3): 235-260. DOI: 10.1159/000488035.
[11]	GAO YR, CHEN SJ, HOU YW, et al. Clinical effect of Huaier Granule sequential with radiofrequency ablation and TACE in treating primary hepatic carcinoma[J]. J Changchun Univ Chin Med, 2020, 36(4): 684-687. DOI: 10.13463/j.cnki.cczyy.2020.04.021. 高远韧, 陈思佳, 侯英文, 等. TACE联合射频消融术序贯槐耳颗粒治疗原发性肝癌[J]. 长春中医药大学学报, 2020, 36(4): 684-687. DOI: 10.13463/j.cnki.cczyy.2020.04.021.
[12]	WANG H, SHAN L, WU XX, et al. Clinical efficacy of Qinggan Quai recipe combined with hepatic artery chemoembolization in the treatment of advanced heat stasis liver cancer[J]. Clin J Med Offic, 2021, 49(3): 306-308. DOI: 10.16680/j.1671-3826.2021.03.23. 王昊, 单良, 吴孝雄, 等. 清肝祛癌方联合肝动脉化疗栓塞术治疗晚期热瘀型肝癌临床疗效[J]. 临床军医杂志, 2021, 49(3): 306-308. DOI: 10.16680/j.1671-3826.2021.03.23.
[13]	LIU CH. Change of understanding of liver cirrhosis and some key points of research[J]. Chin J Integr Tradit West Med Liver Dis, 2014, 24(1): 1-6. DOI: 10.3969/j.issn.1005-0264.2014.01.001. 刘成海. 对肝硬化认识的改变与部分研究重点[J]. 中西医结合肝病杂志, 2014, 24(1): 1-6. DOI: 10.3969/j.issn.1005-0264.2014.01.001.
[14]	REN KW, LI YH, WU G, et al. Quercetin nanoparticles display antitumor activity via proliferation inhibition and apoptosis induction in liver cancer cells[J]. Int J Oncol, 2017, 50(4): 1299-1311. DOI: 10.3892/ijo.2017.3886.
[15]	BRITO AF, RIBEIRO M, ABRANTES AM, et al. New approach for treatment of primary liver tumors: The role of quercetin[J]. Nutr Cancer, 2016, 68(2): 250-266. DOI: 10.1080/01635581.2016.1145245.
[16]	YEE SB, CHOI HJ, CHUNG SW, et al. Growth inhibition of luteolin on HepG2 cells is induced via p53 and Fas/Fas-ligand besides the TGF-β pathway[J]. Int J Oncol, 2015, 47(2): 747-754. DOI: 10.3892/ijo.2015.3053.
[17]	LI Y, WANG WM, CAO M, et al. Effects of insulin on proliferation, invasion and apoptosis of hepatocellular carcinoma cells[J]. Chin J Integr Tradit West Med Liver Dis, 2018, 28(5): 297-299, 306. DOI: 10.3969/j.issn.1005-0264.2018.05.012. 李燕, 王卫民, 曹萌, 等. 胰岛素对肝癌细胞增殖、侵袭、凋亡的影响及机制[J]. 中西医结合肝病杂志, 2018, 28(5): 297-299, 306. DOI: 10.3969/j.issn.1005-0264.2018.05.012.
[18]	HE G, DHAR D, NAKAGAWA H, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling[J]. Cell, 2013, 155(2): 384-396. DOI: 10.1016/j.cell.2013.09.031.
[19]	WANG HM. Reciprocal control of miR-197 and IL-6/STAT3 pathway in hepatocellular carcinoma[D]. Hangzhou: Zhejiang University, 2015. 王华敏. miR-197与IL6/STAT3信号通路相互调控在肝癌生长的作用及机制研究[D]. 杭州: 浙江大学, 2015.
[20]	PANVICHIAN R, TANTIWETRUEANGDET A, SORNMAYURA P, et al. Missense mutations in exons 18-24 of EGFR in hepatocellular carcinoma tissues[J]. Biomed Res Int, 2015, 2015: 171845. DOI: 10.1155/2015/171845.
[21]	ALTIMARI A, FIORENTINO M, GABUSI E, et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours[J]. Dig Liver Dis, 2003, 35(5): 332-338. DOI: 10.1016/s1590-8658(03)00077-x.
[22]	NIU J. Mechanism of P300-dependent acetylation of H3 contributes to EGF-mediated DKK1 transcription and hepatocellular carcinoma metastasis[D]. Kaifeng: Henan University, 2020. 牛杰. P300乙酰化H3促进EGF介导的DKK1转录及肝癌转移的机制研究[D]. 开封: 河南大学, 2020.
[23]	SCHUMANN DM, MAEDLER K, FRANKLIN I, et al. The Fas pathway is involved in pancreatic beta cell secretory function[J]. Proc Natl Acad Sci U S A, 2007, 104(8): 2861-2866. DOI: 10.1073/pnas.0611487104.
[24]	CHOI D, RADZISZEWSKA A, SCHROER SA, et al. Deletion of Fas in the pancreatic beta-cells leads to enhanced insulin secretion[J]. Am J Physiol Endocrinol Metab, 2009, 297(6): e1304-e1312. DOI: 10.1152/ajpendo.00217.2009.

Relative Articles

[1]	Ru JIA, Pingping ZHANG, Yuan YUAN, Yiyang HU, Qin FENG. Differences and application value of plasma bile acids in tumors of the liver[J]. Journal of Clinical Hepatology, 2024, 40(10): 2042-2048. doi: 10.12449/JCH241018
[2]	Tingting ZHU, Jingshu QI, Yanan GUO, Hongliang LIU, Yanyan TAO, Zhimin ZHAO, Zhengxin LI, Chenghai LIU. Effect of Fuzheng Huayu prescription on hepatocyte extinction and regeneration in a mouse model of liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(4): 745-752. doi: 10.12449/JCH240417
[3]	Hui HUANG, Lieming XU, Jian PING, Yang ZHOU. Value of Fuzheng Huayu prescription in preventing liver fibrosis by altering the phenotypic function of CD8⁺ T lymphocytes in the liver of mice with acute liver injury[J]. Journal of Clinical Hepatology, 2022, 38(2): 342-346. doi: 10.3969/j.issn.1001-5256.2022.02.017
[4]	Lijie MA, Xiaojun ZHU, Jiacheng LIN, Fang WANG, Xuehua SUN, Yueqiu GAO. Mechanism of Lingmao Formula in treatment of chronic hepatitis B based on network pharmacology and animal experiment[J]. Journal of Clinical Hepatology, 2022, 38(7): 1503-1508. doi: 10.3969/j.issn.1001-5256.2022.07.010
[5]	Tian ZHANG, Sijing JIA, Dongxue SUN, Fengxi LONG, Dongxin TANG, Zhu YANG. Mechanism of "Szechwan Chinaberry Fruit-Rhizoma Corydalis" drug combination in treatment of liver cancer based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(9): 2136-2143. doi: 10.3969/j.issn.1001-5256.2021.09.026
[6]	Xi GUAN, Wei LIU, Jiamei CHEN, Yongping MU, Ping LIU, Ying XU. Research advances in the clinical and basic research on Fuzheng Huayu prescription in treatment of chronic liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(6): 1449-1453. doi: 10.3969/j.issn.1001-5256.2021.06.048
[7]	Qiuluo CHENG, Liu LIU, Changchuan BAI, Qingwei CONG, Ying ZHU. Mechanism of action of five classic prescriptions in treatment of hepatocellular carcinoma based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(8): 1848-1855. doi: 10.3969/j.issn.1001-5256.2021.08.020
[8]	Shaohang LAN, Qiuyuan TANG, Nana LI, Ran TAO, Nansheng LIAO, Yinjie MENG, Cao HE, Dewen MAO. Mechanism of action of Xiaochaihu decoction in the treatment of hepatitis B based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(10): 2308-2315. doi: 10.3969/j.issn.1001-5256.2021.10.010
[9]	Le TIAN, Yinghang WANG, Zhi PAN. Mechanism of Xiaozheng Huoluo prescription in preventing liver fibrosis in rats via the ERK5 pathway: An analysis based on network pharmacology[J]. Journal of Clinical Hepatology, 2021, 37(3): 582-589. doi: 10.3969/j.issn.1001-5256.2021.03.016
[10]	ZHANG ZhongLin, YUAN YuFeng. Key operating points of laparoscopic hepatectomy for liver tumor in difficult locations[J]. Journal of Clinical Hepatology, 2020, 36(12): 2663-2666. doi: 10.3969/j.issn.1001-5256.2020.12.006
[11]	Li Jing, Mo JiaHao, Xu HongBin, Zhu JunXia, Shi PeiYu, Xing WanLi, Zhong Chong, Lin LiZhu. Mechanism of action of Sini powder in treatment of liver cancer based on network pharmacology and molecular docking[J]. Journal of Clinical Hepatology, 2020, 36(9): 1998-2004. doi: 10.3969/j.issn.1001-5256.2020.09.018
[12]	Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
[13]	Wang ZhiYu, Gu SanWei, Chen XiaoQian, Cai YanJun. Clonorchiasis misdiagnosed as hepatic tumor: a case report[J]. Journal of Clinical Hepatology, 2018, 34(3): 602-603. doi: 10.3969/j.issn.1001-5256.2018.03.033
[14]	Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
[15]	Wang QingLan, Tao YanYan, Lu: Jing, Liu Ping, Liu ChengHai. Antifibrotic mechanism of Fuzheng Huayu prescription by regulation of the differential expression of microRNAs in mouse liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 503-508. doi: 10.3969/j.issn.1001-5256.2016.03.022
[16]	Wang WeiZhen, Meng MingHui, Kong Li, Zhang QingShan, Zhao SuXian, Nan YueMin. Role of Jak /Stat pathway in CCl4- induced rat liver fibrosis model and molecular action mechanism of Fuzheng Huayu recipe in treatment of liver fibrosis[J]. Journal of Clinical Hepatology, 2014, 30(4): 344-348. doi: 10.3969/j.issn.1001-5256.2014.04.014
[17]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[19]	Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	何平，徐婧怡，张雪雪，陈晓龙. 丙酚替诺福韦联合扶正化淤片对乙肝肝硬化代偿期肝纤维化的影响. 中国实用医刊. 2024(02): 118-120 .
2.	蒋式骊，范海纳，刘平，刘成海. 肝硬化并发肝癌的中西医结合诊治现状与评述. 上海中医药杂志. 2023(08): 21-26 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (818) PDF downloads(69)

Mechanism of action of Fuzheng Huayu prescription in treatment of liver cancer based on network pharmacology

DOI: 10.3969/j.issn.1001-5256.2021.10.016